James R. Gavin III, MD, PhD - Swimming in Cloudy Water: Using the Latest Guidelines to Clear Up Clinical Confusion About T2DM Management

Go online to PeerView.com/NXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for prostate cancer has evolved rapidly in recent years, and research endeavors continue to expand treatment options, with significant implications for patients with early-stage and advanced disease. In addition to the approval of multiple second-generation anti-androgen therapies in nonmetastatic castration-resistant and metastatic hormone-sensitive prostate cancer, current clinical trials are investigating novel targeted therapies, immunotherapies, and combination approaches in different disease settings. When managing patients with prostate cancer, clinicians must consider established, newly approved, and emerging therapies throughout the disease continuum, as well as individual patient-, tumor-, and treatment-related factors. Questions that frequently arise include: What is the impact of using anti-androgen therapies earlier in the treatment plan? What is the ideal way to sequence therapies in different disease settings? How should therapy be personalized to ensure that each patient with prostate cancer receives the right treatment? Answers to these and other thought-provoking queries are provided by a panel of prostate cancer experts in this PeerView Talks CME-certified on-demand activity based on a recent live symposium at the American Society of Clinical Oncology Annual Meeting 2019 (ASCO 2019) in Chicago, Illinois. Utilizing an innovative educational design, the experts relate engaging patient stories and link them to practical clinical considerations, enabling learners to better connect evidence to everyday practice. Upon completion of this activity, participants should be better able to: Discuss the clinical evidence, latest guidelines, and expert recommendations for selection and sequencing of hormonal, anti-androgen, cytotoxic, bone-directed, molecularly targeted, and other therapies throughout the disease continuum for patients with hormone-naïve, hormone-sensitive, or castration-resistant, nonmetastatic, and metastatic prostate cancer, Develop personalized, evidence-based treatment plans for patients with early-stage and advanced prostate cancer with considerations of tumor-, patient-, and treatment-related factors, Summarize current and planned clinical trials assessing novel strategies with potential to improve outcomes in different prostate cancer settings.